Fujifilm makes yet another deal to jack up cell and gene therapy capacitynews2022-03-23T01:13:47+00:00March 23rd, 2022|Fierce Pharma|
‘No small feat’: Albireo CEO talks biotech’s commercial transition amid Bylvay launchnews2022-03-22T19:07:29+00:00March 22nd, 2022|Fierce Pharma|
Merck, building on Keytruda’s landmark biomarker nod, pressures GSK’s limited I-O position with new FDA approvalnews2022-03-22T14:10:41+00:00March 22nd, 2022|Fierce Pharma|
As rivals eye ‘unjustified royalties,’ Pfizer partner sues to defend COVID-19 shot Comirnatynews2022-03-22T13:37:27+00:00March 22nd, 2022|Fierce Pharma|
Pfizer pulls blood pressure medicines in US over cancer-causing impuritiesnews2022-03-22T13:36:13+00:00March 22nd, 2022|Fierce Pharma|
Takeda’s Natpara relaunch bid falls flat as manufacturing concerns drag onnews2022-03-22T13:22:32+00:00March 22nd, 2022|Fierce Pharma|
UK watchdog slaps AZ, Allergan, GSK, Sanofi and Britannia for marketing breachesnews2022-03-22T12:43:40+00:00March 22nd, 2022|Fierce Pharma|
Argenx’s subcutaneous Vyvgart matches IV sibling in phase 3, clearing path to FDA filing this yearnews2022-03-22T10:52:36+00:00March 22nd, 2022|Fierce Pharma|
With midphase data in hand, MediPrint lands investment to take drug delivery contact lens deeper into the clinicnews2022-03-22T10:11:08+00:00March 22nd, 2022|Fierce Pharma|
Vallon’s abuse-resistant Adderall fails clinical trial, causing stock to craternews2022-03-22T10:05:33+00:00March 22nd, 2022|Fierce Pharma|
